Latest News and Press Releases

Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens...

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...

Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to...

WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to...

First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and...

WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...

WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...

MORF-057 well tolerated in all dose cohorts MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 receptor ...

Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases Expanded research and...

WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...